Threshold Pharmaceuticals, Inc.

University of Michigan

Smithkline Beecham Corporation

Immunogenesis, Inc.

Stewart Kroll

Jian-Xin Duan

Mark D Matteucci

Richard L Wahl

Harold E Selick

Charles Praray Hart

Kenneth R Zasadny

Jessica Sun

John G Curd

Damian Handisides

Jeffry A Siegal

Jessica D Sun

John Curd

Charles P Hart

Cancer can be treated by administration of a hypoxia-activated prodrug, such as TH-302, alone or in combination with other anticancer agents and/or radiation therapy. In combination therapy, the hypoxia-activated prodrug and another anti-cancer agent or radiation therapy may be administered within the same 24-hour period, and administration of the hypoxia-activated prodrug may be completed prior to beginning administration of the other anticancer agent or radiation therapy.

Treatment of cancer using hypoxia activated prodrugs

The co-administration of glufosfamide and a glucose lowering drug other than insulin is efficacious in cancer treatment.

Treatment of cancer with glufosfamide in patients not receiving insulin therapy

A patient-specific optimally effective radiation dose for administration of a radiopharmaceutical to a patient for treatment of a disease may be established by basing the calculation of the appropriate therapeutic dose on factors such as the desired total body dose, the maximum tolerated dose, the typical clearance profile of the radiopharmaceutical, the patient's mass or maximum effective mass, and the patient-specific residence time of the radiopharmaceutical or an analog in the whole body of the patient. The use of the method allows for treatment of a patient with an appropriate dose which is maximally effective against the disease yet minimally toxic. The determination of a patient-specific therapeutic dose may be assisted by the use of a software program set to the particular parameters of the radiopharmaceutical.

Patient-specific dosimetry

Growing community of inventors

Oakland, CA, United States of America

Stewart Kroll